Skip to content

Effects of Damask rose syrup on menopausal women

Effect of Damask rose syrup on quality of life and menopausal symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250226064861N1
Enrollment
112
Registered
2025-04-10
Start date
2025-03-10
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause. Menopausal and other perimenopausal disorders

Interventions

Intervention 1: Intervention group: Daily consumption of 5 cc of syrup containing one gram of rose extract prepared by Kimia Teb company for a duration of 8 weeks. Intervention 2: Control group: A dai

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 55 Years

Inclusion criteria

Inclusion criteria: The ability to read and write at a basic level Iranian nationality, and residing in the city of Ahvaz age between 45 to 55 years who have had at least one year since their last menstrual period experience of spontaneous amenorrhea for a consecutive duration of 12 months, achieving a score of 116-174 from the menopause quality of life questionnaire and scoring 36 or higher on the MRS questionnaire.

Exclusion criteria

Exclusion criteria: Receiving any type of herbal medicine and phytoestrogens for menopausal symptoms during the study (from start to finish) previous or current history of malignant tumors (all types of tumors) suffering from chronic diseases such as diabetes, liver diseases, thyroid, kidney, gastrointestinal, heart, asthma, endocrine diseases, and urinary genital disease use of anti-anxiety and antidepressant medications in the past three months, hormonal treatment for menopausal symptoms in the past two weeks having undergone oophorectomy and hysterectomy history of radiation therapy and chemotherapy allergy to rose hips alcohol and drug use

Design outcomes

Primary

MeasureTime frame
Quality of life score from the MENQOL questionnaire and menopausal symptom score from the MRS questionnaire. Timepoint: At the beginning of the study and 4 weeks after the start of the intervention and 8 weeks after the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: MENQOL questionnaire and MRS questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvaneh Mousavi

Ahvaz University of Medical Sciences

p-mousavi@ajums.ac.ir+98 61 3311 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026